Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
Not Confirmed
Not Confirmed
17-21 January, 2026
Not Confirmed
Not Confirmed
21-22 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
Industry Trade Show
Not Confirmed
17-21 January, 2026
Industry Trade Show
Not Confirmed
21-22 January, 2026
Digital content
NEWS #PharmaBuzz
29 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/tabuk-launches-vibativ-fda-approved-antibiotic-with-life-saving-potential-in-saudi-arabia-302568865.html
26 Dec 2024
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/bio-thera-solutions-partners-with-tabuk-pharmaceuticals-to-commercialize-bat2206-a-stelara-ustekinumab-biosimilar-in-saudi-arabia-302338862.html
27 Sep 2024
// EXPRESSPHARMA
https://www.expresspharma.in/biocon-signs-licensing-agreement-with-tabuk-pharmaceuticals-for-glp-1-products/
10 May 2024
// PHARMACEUTICAL TECHNOLOGY
https://www.pharmaceutical-technology.com/news/formosa-tabuk-ophthalmic-suspension/
01 Jun 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/levolta-pharmaceuticals-partners-with-tabuk-pharmaceuticals-for-commercialization-of-investigational-osteoarthritis-therapy-in-middle-east-and-africa-301840528.html
31 Mar 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/tabuk-and-cumberland-partner-to-bring-innovative-antibiotic-with-life-saving-potential-to-middle-east-301514843.html
Drugs in Development
Details:
Tabuk has the exclusive rights for commercialization and marketing of K-CAB (tegoprazan), a novel potassium-competitive acid blocker, to include additional six countries in the MENA region.
Lead Product(s): Tegoprazan
Therapeutic Area: Gastroenterology Brand Name: K-CAB
Study Phase: Approved FDFProduct Type: Miscellaneous
Recipient: HK inno.N
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 07, 2025
Lead Product(s) : Tegoprazan
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Recipient : HK inno.N
Deal Size : Undisclosed
Deal Type : Licensing Agreement
HK inno.N and Tabuk Expand Cooperation on New Drug K-CAB for GERD for 6 MENA Countries
Details : Tabuk has the exclusive rights for commercialization and marketing of K-CAB (tegoprazan), a novel potassium-competitive acid blocker, to include additional six countries in the MENA region.
Product Name : K-CAB
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 07, 2025
Details:
Through the partnership, Tabuk will have exclusive rights to manufacture, distribute, and market the BAT2206 (ustekinumab), a biosimilar to Jansen's Stelara in Saudi Arabia.
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Recipient: Bio-Thera Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 24, 2024
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Recipient : Bio-Thera Solutions
Deal Size : Undisclosed
Deal Type : Partnership
Bio-Thera, Tabuk Partner to Market BAT2206 Biosimilar in Saudi Arabia
Details : Through the partnership, Tabuk will have exclusive rights to manufacture, distribute, and market the BAT2206 (ustekinumab), a biosimilar to Jansen's Stelara in Saudi Arabia.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
December 24, 2024
Details:
The agreement will focus on commercialising GLP-1 products for diabetes and chronic weight management in select countries of the Middle East.
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Undisclosed
Sponsor: Biocon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 27, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Biocon
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Biocon Signs Licensing Agreement with Tabuk Pharmaceuticals for GLP-1 Products
Details : The agreement will focus on commercialising GLP-1 products for diabetes and chronic weight management in select countries of the Middle East.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 27, 2024
Details:
Tabuk gains rights to APP13007 (clobetasol propionate) for post-ocular surgery pain and inflammation in the MENA region.
Lead Product(s): Clobetasol Propionate
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Steroid
Recipient: Formosa Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 09, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Formosa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk for Clobetasol
Details : Tabuk gains rights to APP13007 (clobetasol propionate) for post-ocular surgery pain and inflammation in the MENA region.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Undisclosed
May 09, 2024
Details:
Tabuk has the exclusive rights for commercialization and marketing of K-CAB (tegoprazan), a novel potassium-competitive acid blocker, in the Middle East and North Africa.
Lead Product(s): Tegoprazan
Therapeutic Area: Gastroenterology Brand Name: K-CAB
Study Phase: Approved FDFProduct Type: Miscellaneous
Recipient: HK inno.N
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 23, 2024
Lead Product(s) : Tegoprazan
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Recipient : HK inno.N
Deal Size : Undisclosed
Deal Type : Licensing Agreement
HK inno.N and Tabuk Partner to Bring K-CAB (tegoprazan) to the MENA Region
Details : Tabuk has the exclusive rights for commercialization and marketing of K-CAB (tegoprazan), a novel potassium-competitive acid blocker, in the Middle East and North Africa.
Product Name : K-CAB
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 23, 2024
Details:
The agreement aims for the commercialization of an investigational osteoarthritis (OA) therapy, VOLT01 (zoledronic acid), a patented novel combination drug, in the Middle East and Africa (MEA) region, excluding South Africa.
Lead Product(s): Zoledronic Acid Derivative
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Recipient: Levolta Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 01, 2023
Lead Product(s) : Zoledronic Acid Derivative
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II/ Phase III
Recipient : Levolta Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The agreement aims for the commercialization of an investigational osteoarthritis (OA) therapy, VOLT01 (zoledronic acid), a patented novel combination drug, in the Middle East and Africa (MEA) region, excluding South Africa.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 01, 2023
Details:
Vibativ® (telavancin) Injection was discovered in a research program dedicated to finding new antibiotics for serious infections due to Staphylococcus aureus (S. aureus) and other Gram-positive bacteria, including MRSA and MSSA.
Lead Product(s): Telavancin Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Brand Name: Vibativ
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Recipient: Cumberland Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 31, 2022
Lead Product(s) : Telavancin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Cumberland Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Details : Vibativ® (telavancin) Injection was discovered in a research program dedicated to finding new antibiotics for serious infections due to Staphylococcus aureus (S. aureus) and other Gram-positive bacteria, including MRSA and MSSA.
Product Name : Vibativ
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
March 31, 2022
Details:
Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorisation for select speciality products including Glaricon and be responsible to register, importing, and promoting them in Saudi Arabia and other Middle East countries.
Lead Product(s): Insulin Glargine
Therapeutic Area: Endocrinology Brand Name: Glaricon
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Sponsor: Biocon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 07, 2021
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Biocon
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorisation for select speciality products including Glaricon and be responsible to register, importing, and promoting them in Saudi Arabia and other Middle East countries...
Product Name : Glaricon
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
December 07, 2021
Details:
Tabuk Pharmaceuticals will hold the marketing authorization for the Moderna COVID-19 vaccine, mRNA-1273 in Saudi Arabia. The agreement also gives Tabuk the possibility to discuss opportunities to distribute other Moderna mRNA products if authorized in the future.
Lead Product(s): TAK-919
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Oligonucleotide
Recipient: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 11, 2021
Lead Product(s) : TAK-919
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Moderna and Tabuk Pharmaceuticals Partner to Commercialize Moderna’s COVID-19 Vaccine in Saudi A...
Details : Tabuk Pharmaceuticals will hold the marketing authorization for the Moderna COVID-19 vaccine, mRNA-1273 in Saudi Arabia. The agreement also gives Tabuk the possibility to discuss opportunities to distribute other Moderna mRNA products if authorized in th...
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
June 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Inspections and registrations
ABOUT THIS PAGE
Share 
